InsiderTrades

Form 4 for EW Edwards Lifesciences

Accepted 2023-05-09 00:00:00 ET · period of report 2023-05-07 · accession 0001225208-23-005620 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2023-05-09 2023-05-07+ EW Wood Larry L CVP, Grp Pres TAVR, SSH F - Tax $88.74 -4,055 207.8K -2% -$359.8K
D 2023-05-09 2023-05-07 EW Wood Larry L CVP, Grp Pres TAVR, SSH M - OptEx $0.00 +5,415 210.4K +3% $0
D 2023-05-09 2023-05-07 EW Wood Larry L CVP, Grp Pres TAVR, SSH M - OptEx $0.00 -5,415 1,485 -78% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-05-08 F D 1,472 $88.74 206,310.71 D — —
2 Common Common Stock 2023-05-07 F D 2,583 $88.74 207,782.71 D — —
3 Common Common Stock 2023-05-07 M A 5,415 $0.00 210,365.71 D — — (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.
4 Derivative Performance Rights 2023-05-07 M D 5,415 $0.00 1,485 D — · 2023-05-07 to 2027-05-06 5,415 Common Stock (F1) On May 7, 2020, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 1, 2023, the Compensation Committee of the Board of Directors determined that 78.48% of the target number of shares would vest as of May 1, 2023, and the actual number of shares vested are reflected on this Form 4.